|
NuvaRing®, manufactured by Organon, has been linked If you or a loved one have used NuvaRing ®
Call us. We are a team of experienced lawyers who can
Our ability to try cases sets us apart from You pay NO ATTORNEY FEES unless we recover compensation for you. Powell Law Firm, L.C. |
More Information on Nuvaring Side Effects Background NuvaRing is the trade name for a combined hormonal contraceptive vaginal ring manufactured by Organon that is available by prescription. It is a flexible plastic (ethylene-vinyl acetate copolymer) ring that releases a low dose of a progestin and an estrogen over 3 weeks. NuvaRing was first approved in The Netherlands on February 14, 2001, then by
all 14 other countries then in the European Union on June 12, 2001, and in the
United States by the FDA on
October 3, 2001.[1] NuvaRing was first marketed in the United
States in July 2002, followed by several other European countries in late
2002.[2] In March 2007, Organon announced the market
launch of NuvaRing in Australia, bringing the total number of countries where
NuvaRing is available to 32. NuvaRing is currently used by approximately 1.5
million women worldwide In March 2008, a nuvaring side effects lawsuit was filed against the manufacturers, distributors,
and marketers of NuvaRing. The plaintiff alleges that these companies concealed
the health risks associated with using the device, which is claimed to have
cause the death of the plaintiff's wife. It releases the hormones estrogen and progesterone into the bloodstream. The nuvaring side effects problem is that these high levels of hormones can cause blood clotting issues, such as the formation of an embolus (a blood clot) and this could cause severe health consequences. These types of health risk were known and documented for several years, In 2003 the New England Journal of Medicine published two studies that
concluded that the use of low-estrogen oral contraceptives
containing the progestin desogestrel significantly increases the
risk of venous thromboembolism, a potentially fatal type of blood
clot, more than low-estrogen birth control pills containing levonorgestrel.  In two large studies, over a one year period, 15.1% of users discontinued NuvaRing because of adverse events. Device-related adverse events (foreign body sensation, coital problem, or expulsion) were the most frequently reported adverse events that resulted in discontinuation (by 2.5% of users). Device-related adverse events were reported at least once during the one year study period by 4.4% of NuvaRing users.[10] The most common adverse events reported by 5 to 14% of the 2501 women who used NuvaRing in five clinical trials were: vaginitis (14.1%), headache (9.8%), upper respiratory tract infection (8.0%), leukorrhea (5.8%), sinusitis (5.7%), nausea (5.2%), and weight gain (4.9%).[8][15][16] NuvaRing is weight neutral.[17][18] Additional side effect information is provided in the NuvaRing full prescribing information.[8][16] Etonogestrel, the specific progestin used in NuvaRing, is the active metabolite of the inactive prodrug desogestrel, one of two third-generation progestins found in some epidemiological studies of combined oral contraceptive pills to be associated with a higher risk of venous thrombosis than combined oral contraceptive pills containing certain second-generation progestins. Because hormones are released continuously from NuvaRing, peak and total estrogen and progestin doses are significantly lower than with combined oral contraceptives, although it is not known whether this lowers the risk of blood clots.[8] LawsuitIn March 2008, a lawsuit was filed against the manufacturers, distributors,
and marketers of NuvaRing. The plaintiff alleges that these companies concealed
the health risks associated with using the device, which is claimed to have
cause the death of the plaintiff's wife NuvaRing Side Effects to ReportSome side effects with NuvaRing,
while occurring infrequently, are potentially serious and should be reported to
your healthcare provider. These include but are not limited to:
|
|||